Alaunos Therapeutics, Inc. (WEK.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 08:29PM CEST
| Previous close | 1.5800 |
| Open | 1.6000 |
| Bid | 1.5700 x N/A |
| Ask | 1.6000 x N/A |
| Day's range | 1.5500 - 1.6300 |
| 52-week range | 1.1900 - 4.7800 |
| Volume | |
| Avg. volume | 337 |
| Market cap | 340.583M |
| Beta (5Y monthly) | -0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2990 |
| Earnings date | 13 May 2024 - 19 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAlaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Best Response to TCR-T Best Response to TCR-T TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar
© 2024 Yahoo. All rights reserved.